T. Rowe Price and OrbiMed

Selected healthcare news for the capital firm - T. Rowe Price, and the company - OrbiMed. We have 14 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
4/13/2021 Theseus Debuts with $100 Million Series B to for Targeted Treatment-Resistant Cancer Mutations Rare Daily Staff Theseus Pharmaceuticals emerged from stealth with the close of a $100 million series B financing to develop drugs that target treatment-resistant cancer mutations. Forsite Capital led the financing with participation from Adage Capital Management, Boxer Capital, Farallon Capital Management, Longitude Capital, Nextech Ventures, Omega Healthcare Investors, Pontifax Venture Capital, Rock Springs Capital, and T. Rowe Price, as well as OrbiMed, which incubated Theseus and funded its ...
3/31/2021 Scribe Therapeutics Raises $100M Series B Financing to Further Develop “CRISPR by Design” Platform and Pipeline of Breakthrough Genetic Medicines | Business Wire Business Wire ALAMEDA, Calif.--( BUSINESS WIRE )--Scribe Therapeutics Inc., a molecular engineering company creating the most advanced technologies for CRISPR-based genetic medicine, today announced the completion of an oversubscribed $100M Series B financing. Avoro Ventures and Avoro Capital Advisors led the financing joined by OrbiMed Advisors and Andreessen Horowitz. Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, Inc., funds managed by Wellington Management, RA Capital Management, Menlo Ventures ...
3/31/2021 Scribe Therapeutics Raises $100M Series B Financing to Further Develop "CRISPR by Design" Platform and Pipeline of Breakthrough Genetic Medicines Yahoo News ... OrbiMed Advisors and Andreessen Horowitz. Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, Inc., funds managed by Wellington Management, RA Capital Management, Menlo Ventures, and an undisclosed global investment firm also joined the syndicate. As part of the financing, Behzad Aghazadeh, managing partner at Avoro Ventures and Avoro Capital Advisors, and Carl L. Gordon, managing partner at OrbiMed Advisors, will join Scribe‚Aos Board of Directors.The ...
3/31/2021 Scribe Raises $100 Million to Further Develop Its ‚ÄúCRISPR by Design‚Äù Platform Rare Daily Staff Scribe Therapeutics completed an oversubscribed $100 million series B financing to continue developing its ‚AuCRISPR by Design‚Au platform and its pipeline of genetic medicines. Avoro Ventures and Avoro Capital Advisors led the financing joined by OrbiMed Advisors and Andreessen Horowitz. Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, funds managed by Wellington Management, RA Capital Management, Menlo Ventures, and an undisclosed global investment ...
3/31/2021 Scribe Therapeutics Raises $100M Series B Financing to Further Develop ‚ÄúCRISPR by Design‚Äù Platform and Pipeline of Breakthrough Genetic Medicines ... OrbiMed Advisors and Andreessen Horowitz. Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, Inc., funds managed by Wellington Management, RA Capital Management, Menlo Ventures, and an undisclosed global investment firm also joined the syndicate. As part of the financing, Behzad Aghazadeh, managing partner at Avoro Ventures and Avoro Capital Advisors, and Carl L. Gordon, managing partner at OrbiMed Advisors, will join Scribe¬is Board of Directors. The ...
3/31/2021 Scribe Therapeutics Raises $100M Series B Financing to Further Develop CRISPR by Design Platform and Pipeline of Breakthrough Genetic Medicines | Financial Buzz Scribe Therapeutics Inc., a molecular engineering company creating the most advanced technologies for CRISPR-based genetic medicine, today announced the completion of an oversubscribed $100M Series B financing. Avoro Ventures and Avoro Capital Advisors led the financing joined by OrbiMed Advisors and Andreessen Horowitz. Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, Inc., funds managed by Wellington Management, RA Capital Management, Menlo Ventures, and an undisclosed global ...
10/27/2020 Caris Life Sciences Raises $310 Million in Growth Capital from a Broad Syndicate of Leading Investors | BioSpace ... T. Rowe Price Associates, Inc., OrbiMed, Millennium Management, Neuberger Berman, ClearBridge Investments, First Light Asset Management and other undisclosed investors.The Company also raised $75 million in debt from Sixth Street as an extension to the $150 million in structured debt financing Sixth Street invested in September 2018 . Sixth Street also participated in the equity round. Following the conclusion of this financing, Vijay Mohan , Co-founding Partner at Sixth Street ...
10/27/2020 Caris Life Sciences Raises $310 Million in Growth Capital from a Broad Syndicate of Leading Investors ... T. Rowe Price Associates, Inc., OrbiMed, Millennium Management, Neuberger Berman, ClearBridge Investments, First Light Asset Management and other undisclosed investors.The Company also raised $75 million in debt from Sixth Street as an extension to the $150 million in structured debt financing Sixth Street invested in September 2018. Sixth Street also participated in the equity round. Following the conclusion of this financing, Vijay Mohan, Co-founding Partner at Sixth Street, has ...
10/27/2020 Caris Life Sciences Raises $310 Million in Growth Capital from a Broad Syndicate of Leading Investors ... T. Rowe Price Associates, Inc., OrbiMed, Millennium Management, Neuberger Berman, ClearBridge Investments, First Light Asset Management and other undisclosed investors. The Company also raised $75 million in debt from Sixth Street as an extension to the $150 million in structured debt financing Sixth Street invested in September 2018. Sixth Street also participated in the equity round. Following the conclusion of this financing, Vijay Mohan, Co-founding Partner at Sixth Street ...
7/9/2020 VelosBio Raises $137M in Series B ... OrbiMed, funds and accounts advised by T. Rowe Price Associates, Inc., Venrock Healthcare Capital Partners, Viking Global Investors, and Wellington Management Company, which are joining existing investors Arix Bioscience, Decheng Capital, Pappas Capital, Sofinnova Ventures, and Takeda Ventures.The proceeds from the Series B financing will be used to further advance the clinical development of the VelosBio lead antibody-drug conjugate (ADC), VLS-101, and support the continued expansion of its ...
7/8/2020 VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology Business Wire ... OrbiMed, funds and accounts advised by T. Rowe Price Associates, Inc., Venrock Healthcare Capital Partners, Viking Global Investors, and Wellington Management Company, which are joining existing investors Arix Bioscience, Decheng Capital, Pappas Capital, Sofinnova Ventures, and Takeda Ventures. The proceeds from the Series B financing will be used to further advance the clinical development of the VelosBio lead antibody-drug conjugate (ADC), VLS-101, and support the continued expansion of ...
7/8/2020 VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology | BioSpace BioSpace ... OrbiMed, funds and accounts advised by T. Rowe Price Associates, Inc., Venrock Healthcare Capital Partners, Viking Global Investors, and Wellington Management Company, which are joining existing investors Arix Bioscience, Decheng Capital, Pappas Capital, Sofinnova Ventures, and Takeda Ventures. The proceeds from the Series B financing will be used to further advance the clinical development of the VelosBio lead antibody-drug conjugate (ADC), VLS-101, and support the continued expansion of ...
7/8/2020 VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology ... OrbiMed, funds and accounts advised by T. Rowe Price Associates, Inc., Venrock Healthcare Capital Partners, Viking Global Investors, Wellington Management Company, and all existing institutional investors SAN DIEGO, July 8, 2020-- VelosBio Inc. (“VelosBio”), a clinical-stage biopharmaceutical company committed to developing novel, first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), today announced the completion of an oversubscribed Series B financing of $137 million ...
7/8/2020 VelosBio raises $137M Series B round to support suite of ROR1-targeting cancer drugs - MedCity News MedCity News The company is currently running a Phase I study of its lead candidate, the antibody-drug conjugate VLS-101, in patients with lymphomas and leukemias. It has two additional antibody-drug conjugates and a bispecific antibody in preclinical development ...